It's been a pretty wild ride for Alnylam (Nasdaq:ALNY) shareholders, even by the elevated standards of biotechnology. Once thought to have the IP keys to one of the next great platform technologies (RNA interference), the stock was hammered down over several years as multiple Big Pharma companies chose to back away from the technology and partnerships with Alnylam. Since late 2011, though, it's been a return to investor love for Alnylam as positive clinical data and a bull market in biotech has fueled a fourfold rise in the shares.
Please follow the link to continue:
http://www.investopedia.com/stock-analysis/052813/alnylam-basking-orphan-drug-attention-alny-alxn-isis-pfe-amgn.aspx
Investopedia: Alnylam Basking In Orphan Drug Attention
0 comments:
Post a Comment